Telix Pharmaceuticals and IRE Elit Enter Distribution Partnership for Prostate Cancer Imaging
Herstal and Fleurus (Belgium) – 1st September 2020. Telix announces distribution agreement with Fleurus-based IRE Elit S.A. to distribute Telix’s prostate cancer imaging product
Telix Pharmaceuticals Limited is pleased to announce it has entered into an exclusive distribution agreement with Fleurus-based IRE Elit S.A. to distribute Telix’s prostate cancer imaging product TLX591-CDx (68Ga-PSMA-11), a radiopharmaceutical for the imaging of metastatic prostate cancer.
Under the terms of the agreement, IRE has been appointed as the exclusive commercial distributor of TLX591-CDx in France and French overseas territories, during both the initial period of ‘autorisation d’exploitation temporaire’ (temporary authorisation) and once full European marketing authorisation is granted in 2021.
TLX591-CDx does not have a marketing authorisation in any jurisdiction.
To read full media release please click here.
Telix New Drug Application for Prostate Cancer Imaging Product Accepted by US FDA
Melbourne (Australia) and Indianapolis, IN (U.S.A.) – 24th November 2020. Telix Pharmaceuticals announces New Drug Application (NDA) for TLX591-CDx (Kit...
Telix Presentation at the European Multidisciplinary Congress on Urological Cancers
20th November 2020 | Corporate Spotlight | Recording of Live Presentation at EMUC20 Virtual Congress: New Perspectives in Prostate and...
Telix Receives €545,000 Belgian Research Grant for Prostate Cancer Imaging Agent in Europe
Melbourne (Australia) and Liège (Belgium) – 19th November 2020. Advanced Nuclear Medicine Ingredients S.A. (ANMI) announces a €545,000 payment from...
Telix presentations at European Association of Nuclear Medicine 2020 Satellite Symposium
13th November 2020 | Corporate Spotlight – Recording of live presentations at EANM Virtual Symposium: Next Generation Imaging with PSMA-PET...
Investor Briefing: Telix Pharmaceuticals Limited and China Grand Pharma Partnership
Melbourne (Australia) – 3rd November 2020. Telix Pharmaceuticals Provides Investor Briefing: Our Asian Future
Telix Pharmaceuticals Limited and China Grand Pharma Announce Strategic Licence and Commercial Partnership for Greater China Market
Melbourne (Australia) and Hong Kong SAR (China) – 2nd November 2020. Telix Pharmaceuticals Limited and China Grand Pharma Announce Strategic...
Activity Report and Sales Note to Accompany Appendix 4C
Melbourne (Australia) – 30th October 2020. Telix Pharmaceuticals provides its Activity Report and Appendix 4C for the quarter ending 30th September 2020,...
Telix Japan to Present at Japanese Society of Nuclear Medicine Annual Scientific Meeting
28th October 2020 – Clinical Spotlight | Telix Japan to Present at Japanese Society of Nuclear Medicine Annual Scientific Meeting
Telix Completes Licence Agreement with German Cancer Research Center (DKFZ) for Image-Guided Prostate Surgery
Melbourne (Australia) and Heidelberg, (Germany) – 28th October 2020. Telix has secured an exclusive Intellectual Property licence agreement with the...
Completion of Phase I Enrolment of Japanese Renal Cancer Study
Tokyo (Japan) – 27th October 2020. Telix Pharmaceuticals Japan K.K. is pleased to announce the completion of Phase I enrolment...